Blood pressure lowering efficacy of renin inhibitors for primary hypertension: A Cochrane systematic review

Journal of Human Hypertension

Volumn 23, Issue 8, 2009, Pages 495-502

  Musini, V M ^a   Fortin, P M ^a   Bassett, K ^a   Wright, J M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO; RENIN INHIBITOR; VALSARTAN;

ANGIONEUROTIC EDEMA; BACKACHE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ADULT; AMIDES; ANGIOEDEMA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COUGH; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMARATES; HEART RATE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67849128863     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.162     Document Type: Review

References (13)

1. Helmer OM. Studies on renin antibodies. Circulation 1958; 17 648-652.
2. Frishman WH, Fozailoff A, Lin C, Dike C. Renin inhibition: A new approach to cardiovascular therapy. J Clin Pharmacol 1994; 34 873-880.
3. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25: 25-35.
4. Kushiro T, Hiroshige I, Yoshihisa A, Hiromi G, Shinji T, Keefe D. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
5. Pool J, Roland E, Schmieder M, Aldigier JC, Januszewicz A, Zidek W et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20.
6. Villamil A, Chrysant S, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-226.
7. Oparil S, Yarrows S, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007; 370: 221-229.
8. Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
9. Oh B, Mitchell J, Herron J, Chung J, Khan ML, Keefe D. Aliskiren, an oral renin inhibitor, provides dose dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
10. Duprez D. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. J Hypertens 2006; 24: 983-991.
11. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Syst Rev 2008; Issue 4. Art. No.: CD003823. doi:10.1002/14651858.CD003823.pub2.
12. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Syst Rev 2008; Issue 4. Art. No.: CD003822. doi:10.1002/14651858.CD003822.pub2.
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003; 326: 1427.